| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699271 | Clinical Oncology | 2011 | 7 Pages |
Abstract
Single-agent carboplatin has modest activity in patients with recurrent HGG who have received at least two lines of chemotherapy. The overall time to progression is short and over two-thirds of patients had to discontinue treatment due to progressive disease. Among the small proportion of patients achieving stable disease or a partial response to treatment, the median survival is improved. More effective but well tolerated regimens are required for this patient population.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
L.J. Murray, C.H. Bridgewater, D. Levy,